Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its Board of
Directors has approved a two-for-one stock split of the company's
outstanding common stock to be effected through a stock dividend.
Stockholders of record as of the close of business on January 7, 2013
will be entitled to a stock dividend of one additional share of common
stock for every share of common stock they own. Based on the total
number of shares of common stock outstanding as of November 30, 2012,
the stock split will increase the total number of shares of common stock
outstanding from approximately 759,335,932 to 1,518,671,864, out of the
2,800,000,000 shares of common stock currently authorized.
The company's transfer agent, Computershare Shareowne Services LLC, has
been instructed to mail a Direct Registration Transaction Advice for the
additional shares to stockholders that have physical possession of their
stock certificates on January 25, 2013. Stockholders who hold their
stock in a brokerage account will receive their new shares through their
broker dealer on or about the same date.
The company's stock will begin trading at the post-split price on
January 28, 2013. Any shares purchased after January 7, 2013 through
January 28, 2013 will come with a "due-bill" entitling the buyer to one
additional share for each share purchased.
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company's mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Asia
For more information on Gilead Sciences, please visit www.gilead.com
or call the Gilead Public Affairs Department at 1-800-GILEAD-5
[ Back To NFVZone's Homepage ]